Genetic analysis of OCT1 gene polymorphisms in an Indian population

Indian Journal of Human Genetics

Volumn 17, Issue 3, 2011, Pages 164-168

  Umamaheswaran, Gurusamy ^a   Praveen, Ramakrishnan G ^a   Arunkumar, Annan S ^a   Das, Ashok K ^a   Shewade, Deepak G ^a   Adithan, Chandrasekaran ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Diabetes; metformin; OCT1; polymorphism

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 1;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; HUMAN; INDIA; MALE; PHARMACOGENETICS; POPULATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84856385546     PISSN: 09716866     EISSN: 1998362X     Source Type: Journal    
DOI: 10.4103/0971-6866.92094     Document Type: Article

References (14)

1. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24:1227-51. (Pubitemid 46876495)
2. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008;9:415-22. (Pubitemid 351803926)
3. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med 2002;137:25-33. (Pubitemid 34705373)
4. Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008;23:243-53.
5. Becker ML, Visser LE, van Shaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009;9:242-7.
6. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007;52:117-22. (Pubitemid 46185105)
7. Shu Y, Leabman KM, Feng B, Mangravite LM, Huang CC, Stryke D, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A 2003;100:5902-7. (Pubitemid 36576905)
8. Kang HJ, Song IS, Shin HJ, Kim WY, Lee CH, Shim JC, et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos 2007;35:667-75.
9. Itoda M, Saito Y, Maekawa K, Hichiya H, Komamura K, Kamakura S, et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet 2004;19:308-12.
10. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86:299-306.
11. Becker ML, Visser LE, van Shaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010;20:38-44.
12. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, et al. OCT1-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced Oct-1 activity is the cause of low invitro sentivity to imatinib. Blood 2006;108:697-704. (Pubitemid 44061372)
13. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83:258-64.
14. Becker ML, Visser LE, van Shaik RH, Hofman A, Uitterlinden AG, Stricker BH. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 2011;12:79-82.